Literature DB >> 9649161

The in vitro radiosensitivity of human head and neck cancers.

T Björk-Eriksson1, C M West, E Karlsson, N J Slevin, S E Davidson, R D James, C Mercke.   

Abstract

A study was made of the intrinsic radiosensitivity of 140 biopsy and surgical specimens of malignant head and neck tumours of different histologies. Using a soft-agar clonogenic assay, the material was assessed for the ability to grow in culture (colony-forming efficiency; CFE) and inherent tumour radiosensitivity (surviving fraction at 2 Gy, SF2). The success rate for obtaining growth was 74% (104/140) with a mean CFE of 0.093% (median 0.031) and a range of 0.002-1.3%. SF2 was obtained for 88 of 140 specimens, representing a success rate of 63% with a mean SF2 of 0.48 (median 0.43) and a range of 0.10-1.00. There were no significant differences in radiosensitivity between different sites of the head and neck region. There were no significant relationships between SF2 and disease stage, nodal status, tumour grade, patient age, primary tumour growth pattern and CFE. The results were compared with those for other tumour types previously analysed with the same assay. The distribution of the SF2 values for the head and neck tumours was similar to that for 145 cervix carcinomas and there was no significant difference in mean radiosensitivity between the two tumour types. Also, there was no significant difference in radiosensitivity between head and neck tumours and either breast or colorectal cancers. However, a group of eight lymphomas was significantly more radiosensitive. These results confirm the feasibility of carrying out radiosensitivity measurements using a soft-agar clonogenic assay on head and neck tumours. In addition, the work has shown that radiosensitivity is independent of many clinical parameters and that the mean value is similar to that reported for cervix carcinomas.

Entities:  

Mesh:

Year:  1998        PMID: 9649161      PMCID: PMC2150420          DOI: 10.1038/bjc.1998.394

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Radiosensitivity of human head and neck squamous cell carcinomas in primary culture and its potential as a predictive assay of tumor radiocurability.

Authors:  W A Brock; F L Baker; L J Peters
Journal:  Int J Radiat Biol       Date:  1989-11       Impact factor: 2.694

2.  The effect of patient-to-patient variability on the accuracy of predictive assays of tumor response to radiotherapy: a theoretical evaluation.

Authors:  S L Tucker; H D Thames
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-07       Impact factor: 7.038

3.  Radiosensitivity testing of primary cervical carcinoma: evaluation of intra- and inter-tumour heterogeneity.

Authors:  S E Davidson; C M West; S A Roberts; J H Hendry; R D Hunter
Journal:  Radiother Oncol       Date:  1990-08       Impact factor: 6.280

4.  Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay.

Authors:  B Stausbøl-Grøn; O S Nielsen; S Møller Bentzen; J Overgaard
Journal:  Radiother Oncol       Date:  1995-11       Impact factor: 6.280

5.  Lack of a relationship between colony-forming efficiency and surviving fraction at 2 Gy.

Authors:  C M West; S E Davidson; C Pool; R D James; P F Schofield
Journal:  Radiat Res       Date:  1991-05       Impact factor: 2.841

6.  Radiation sensitivity in vitro of cells isolated from human tumor surgical specimens.

Authors:  E K Rofstad; A Wahl; T Brustad
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

7.  Radiosensitivity testing of human malignant gliomas.

Authors:  J Ramsay; R Ward; N M Bleehen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

8.  Cellular radiosensitivity of primary head and neck squamous cell carcinomas and local tumor control.

Authors:  W A Brock; F L Baker; J L Wike; S L Sivon; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-06       Impact factor: 7.038

Review 9.  The radioresponsiveness of human tumours and the initial slope of the cell survival curve.

Authors:  J Deacon; M J Peckham; G G Steel
Journal:  Radiother Oncol       Date:  1984-12       Impact factor: 6.280

10.  Growth and radiosensitivity testing of human tumour cells using the adhesive tumour cell culture system.

Authors:  C S Parkins; G G Steel
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

View more
  6 in total

1.  Clinically relevant biomarkers in targeted radiotherapy.

Authors:  Baldassarre Stea; John Gordon
Journal:  Clin Exp Metastasis       Date:  2012-08-11       Impact factor: 5.150

2.  Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time.

Authors:  M Hedman; T Björk-Eriksson; O Brodin; I Toma-Dasu
Journal:  Br J Radiol       Date:  2013-03-11       Impact factor: 3.039

3.  The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers.

Authors:  T Björk-Eriksson; C M West; E Cvetskovska; M Svensson; E Karlsson; B Magnusson; N J Slevin; S Edström; C Mercke
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

4.  Dynamic Characteristics and Predictive Capability of Tumor Voxel Dose-Response Assessed Using 18F-FDG PET/CT Imaging Feedback.

Authors:  Shupeng Chen; An Qin; Di Yan
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

5.  Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.

Authors:  Ross Carruthers; Shafiq U Ahmed; Karen Strathdee; Natividad Gomez-Roman; Evelyn Amoah-Buahin; Colin Watts; Anthony J Chalmers
Journal:  Mol Oncol       Date:  2014-08-24       Impact factor: 6.603

Review 6.  Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review.

Authors:  Amy J C Dohmen; Justin E Swartz; Michiel W M Van Den Brekel; Stefan M Willems; René Spijker; Jacques Neefjes; Charlotte L Zuur
Journal:  Cancers (Basel)       Date:  2015-08-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.